Gene Therapy AMT-061 Shows Clinical Benefit in Hemophilia B Patients in Recent Trial – Rare Disease Report
Seeking Alpha |
Gene Therapy AMT-061 Shows Clinical Benefit in Hemophilia B Patients in Recent Trial
Rare Disease Report New data presented by the gene therapy company uniQure at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting held in Chicago, Illinois, has shown that the company's gene therapy product candidate, AMT-061, is clinically beneficial … UniQure's AMT-060 shows treatment benefit in hemophilia B patients with pre-existing neutralizing antibodies; shares … uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 … |
